You are viewing an expired study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials

Minneapolis, Minnesota

  • Breast Neoplasms

Purpose:

The purpose of this study is to determine whether raloxifene compared with placebo lowers the risk of coronary events and reduces the risk of invasive breast cancer in postmenopausal women at risk for major coronary events.


Criteria:

Inclusion Criteria: - Postmenopausal women with established coronary heart disease or at risk for a major coronary event. Exclusion Criteria: - Postmenopausal symptoms that required estrogen replacement therapy. - Suspected or known history of breast or endometrial carcinoma. - Known or probable history of deep venous thrombosis, pulmonary embolism, or retinal vein thrombosis. - New York Heart Association classes III or IV heart failure.


NCT ID:

NCT00190593


Primary Contact:

Study Director
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Eli Lilly and Company


Backup Contact:

N/A


Location Contact:

Minneapolis, Minnesota
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.